Investments, Funding & Disinvestment

The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.

The project includes a specialised training academy designed to develop advanced skills in biotechnology, quality control, and vaccine production, ensuring a steady pipeline of qualified personnel to support long-term operations and sector growth.

The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.

The company has invested nearly US$5 billion in the United States over the past 15 years, expanding its manufacturing, research, development, and distribution infrastructure.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

The deal was signed at the EAC Headquarters in Arusha, Tanzania, by EAC Secretary General Amb. Stephen P. Mbundi and KfW Development Bank Country Director for Tanzania and the EAC, Ms. Vanessa Eidt.

The expanded network enables the company to reach a broader customer base while strengthening its distribution capabilities across the UAE healthcare ecosystem.

The platform now enables the secure exchange of approvals, billing, and settlements among pharmacies, insurers, and healthcare providers, reducing reliance on manual paperwork by up to 98% in certain processes.